C3a and C5a anaphylatoxin receptors, therapeutic GPCR targets of the complement system
SYnAbs unique therapeutic effector monoclonal antibodies targeting anaphylatoxin C3aR and C5aR GPCR. Functional antibody targeting complex transmembrane proteins and G protein-coupled receptors.
Therapeutic targets of the complement system
The Complement System and its druggable targets by antibodies: C3aR, C5aR GPCR membrane receptors, C3, C4, C5 ligands

Monoclonal antibodies to human CD cell surface antigens
SYnAbs generates innovative functional monoclonals against clusters of differentiation markers, IgG superfamily, and C-type lectin-like receptors (CLRs). Discover how SYnAbs generate Siplizumab anti-human CD2 antibody and other transmembrane effector monoclonals.
Orphan GPCR and their untapped therapeutic potential: the next wave of antibody drug targets?
Untapped therapeutic potential of orphan GPCR and SYnAbs functional monoclonals anti-GPCR. Generation of new antibody therapeutics targeting orphan membrane receptors.

CC chemokine receptors: latest news on Beta chemokine receptor therapeutics
SYnabs generate therapeutic monoclonal antibodies against CC chemokine receptors thanks to modified peptides, DNA and cell immunization strategies
Chemokine receptors: a promising GPCR family to target?
SYnAbs develops anti-chemokine receptors monoclonal antibodies with therapeutic effect for Biotech and Pharma companies

Functional antibodies: B-cell depleting antibodies
To address all B cell depletion needs, SYnAbs has developed monoclonal antibody references, which exhibit the ability to deplete murine or rat B cells in vivo, providing a valuable research tool for its biotech and pharma partners.
SYnAbs and Belgian Volition ink strategic agreement on epigenetics
SYnAbs enters in a strategic agreement with Volition to generate monoclonal antibodies against epigenetics biomarkers including modifications of histones and DNA, histone variants, and proteins associated with nucleosomes

Viral Envelope Proteins,  targets for Therapeutic Neutralizing Antibodies (NAbs)
How to generate effective neutralizing antibodies to target infectious disease transmembrane protein antigens. A review of the technical challenges, strategies, and risks.
Anti-drug antibody generation :  How to effectively monitor your therapeutic drug
SYnabs generate anti-drug antibodies for small molecules and therapeutic antibodies. Paratope-specific anti-idiotype antibodies, non-inhibitory anti-idiotype antibodies, or drug-target complex binders generation.

Show more